The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

Masayuki Kurosaki; Kotaro Matsunaga; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Nobutoshi Komatsu; Naoki Umeda; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yasuhiro Asahina; Shozo Miyake; Nobuyuki Enomoto; Namiki Izumi

doi:10.1016/j.jhep.2007.12.025

Back

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

Journal article

Peer reviewed

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

Masayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Nobutoshi Komatsu, Naoki Umeda, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, …

Journal of hepatology, Vol.48(5), pp.736-742

05/2008

DOI: 10.1016/j.jhep.2007.12.025

PMID: 18329125

View Online

Abstract

Interferon (IFN) therapy leads to regression of hepatic fibrosis in chronic hepatitis C patients who achieve a sustained virologic response (SVR), while the beneficial effect is limited in those who fail to do so. The aim of the present study was to define factors associated with progression of fibrosis in patients who do not achieve a SVR. Fibrosis staging scores were compared between paired liver biopsies before and after IFN in 97 chronic hepatitis C patients who failed therapy. The mean interval between biopsies was 5.9 years. Factors associated with progression of fibrosis were analyzed. Fibrosis progressed in 23%, remained unchanged in 47% and regressed in 29%. Steatosis and a high average alanine aminotransferase (ALT) between biopsies were independent factors for progression of fibrosis with risk ratios of 5.53 and 4.48, respectively. Incidence and yearly rate of progression of fibrosis was 64% and 0.22±0.29 fibrosis units per year in those with both risk factors compared to 8% and −0.04±0.17 fibrosis units per year in those negative for both factors. Hepatic steatosis and elevated ALT levels are risk factors for progression of fibrosis in chronic hepatitis C patients who fail to achieve a SVR to IFN therapy and therefore may be therapeutic targets to halt the potentially progressive disease.

ALT

Fibrosis

Steatosis

Details

Title: Subtitle: The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy
Creators: Masayuki Kurosaki - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Kotaro Matsunaga - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Itsuko Hirayama - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Tomohiro Tanaka - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Mitsuaki Sato - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Nobutoshi Komatsu - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Naoki Umeda - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Takanori Hosokawa - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Ken Ueda - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Kaoru Tsuchiya - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Hiroyuki Nakanishi - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Jun Itakura - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Yasuhiro Asahina - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Shozo Miyake - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Nobuyuki Enomoto - First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan
Namiki Izumi - Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan
Resource Type: Journal article
Publication Details: Journal of hepatology, Vol.48(5), pp.736-742
Publisher: Elsevier B.V
DOI: 10.1016/j.jhep.2007.12.025
PMID: 18329125
ISSN: 0168-8278
eISSN: 1600-0641
Language: English
Date published: 05/2008
Academic Unit: Gastroenterology and Hepatology; Internal Medicine
Record Identifier: 9984094354302771

Metrics

10 Record Views

32 Times Cited - Web of Science